Literature DB >> 23055860

The treatment of migraine headaches in children and adolescents.

Michelle Brenner1, Donald Lewis.   

Abstract

Effective management of migraine headache in children and adolescents requires a balanced approach with an individually tailored regimen targeted to treat an acute attack at its onset, blended with bio-behavioral measures, and, in about 1/3 of patients, daily preventive medicines. The key first step is to assess the disability imposed by the recurrent headache pattern, the headache "burden." Once the burden is established decisions can be made toward selecting the most appropriate course of action. All patients will benefit from some basic bio-behavioral suggestions such as regular sleep, exercise, and eating schedule, moderation of caffeine, and identification of triggers. In addition, all patients should have a readily available analgesic to be used at the onset of a migraine attack. A subset of migraineurs will have sufficient headache burden to necessitate use of daily preventative medications. Unfortunately, there is limited controlled data to provide a comprehensive, evidence-based guideline, however, the most rigorously studied agents for acute treatment are ibuprofen, acetaminophen, and "triptan" nasal spray forms of sumatriptan and zolmitriptan; all of these have shown safety and efficacy in controlled trials. For preventive treatment, flunarizine, not available in the U.S., is the only agent that has demonstrated efficacy in placebo controlled trials, but encouraging data is emerging regarding the use of several antiepileptic agents such as topiramate, disodium valproate, and levetiracetam, as well as the antihistamine cyproheptadine and the antidepressant amitriptyline.

Entities:  

Keywords:  headache; migraine; pharmacotherapy; treatment

Year:  2008        PMID: 23055860      PMCID: PMC3462052          DOI: 10.5863/1551-6776-13.1.17

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  26 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

2.  Topiramate in migraine prevention: a double-blind, placebo-controlled study.

Authors:  J R Storey; C S Calder; D E Hart; D L Potter
Journal:  Headache       Date:  2001 Nov-Dec       Impact factor: 5.887

Review 3.  The treatment of pediatric migraine.

Authors:  Donald W Lewis; Marcy Yonker; Paul Winner; Michael Sowell
Journal:  Pediatr Ann       Date:  2005-06       Impact factor: 1.132

Review 4.  Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.

Authors:  D Lewis; S Ashwal; A Hershey; D Hirtz; M Yonker; S Silberstein
Journal:  Neurology       Date:  2004-12-28       Impact factor: 9.910

5.  Flunarizine v. placebo in childhood migraine. A double-blind study.

Authors:  F Sorge; E Marano
Journal:  Cephalalgia       Date:  1985-05       Impact factor: 6.292

6.  Trigger factors in migraine: a study conducted by the Belgian Migraine Society.

Authors:  V Van den Bergh; W K Amery; J Waelkens
Journal:  Headache       Date:  1987-04       Impact factor: 5.887

7.  Incidence of migraine headache: a population-based study in Olmsted County, Minnesota.

Authors:  P E Stang; P A Yanagihara; J W Swanson; C M Beard; W M O'Fallon; H A Guess; L J Melton
Journal:  Neurology       Date:  1992-09       Impact factor: 9.910

8.  Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.

Authors:  Paul Winner; Steven L Linder; Richard B Lipton; Mary Almas; Bruce Parsons; Verne Pitman
Journal:  Headache       Date:  2007-04       Impact factor: 5.887

9.  Nasal sumatriptan is effective in treatment of migraine attacks in children: A randomized trial.

Authors:  Kati Ahonen; Mirja L Hämäläinen; Heikki Rantala; Kalle Hoppu
Journal:  Neurology       Date:  2004-03-23       Impact factor: 9.910

10.  Age- and sex-specific incidence rates of migraine with and without visual aura.

Authors:  W F Stewart; M S Linet; D D Celentano; M Van Natta; D Ziegler
Journal:  Am J Epidemiol       Date:  1991-11-15       Impact factor: 4.897

View more
  2 in total

Review 1.  Preventive drugs in childhood and adolescent migraine.

Authors:  Joanne Kacperski; Andrew D Hershey
Journal:  Curr Pain Headache Rep       Date:  2014-06

Review 2.  Evidence and consensus recommendations for the pharmacological management of pain in India.

Authors:  Gur Prasad Dureja; Rajagopalan N Iyer; Gautam Das; Jaishid Ahdal; Prashant Narang
Journal:  J Pain Res       Date:  2017-03-29       Impact factor: 3.133

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.